Hepatitis C virus (HCV) infection is a major cause of chronic liver disease and associated
morbidity and mortality worldwide. Short-course, oral, curative, direct-acting antiviral …

Background The effect of direct‐acting anti‐virals (DAAs) in children and adolescents with
chronic hepatitis C virus (HCV) infection is difficult to determine, since few, aged between 3 …

ABSTRACT Introduction: Hepatitis C virus (HCV) infection is an important contributor to the
worldwide burden of liver-related morbidity and mortality. Mother-to-child transmission of …

Abstract Background and Aims We evaluated the effectiveness and safety of pan‐genotypic
regimens, glecaprevir/pibrentasvir (GLE/PIB), sofosbuvir/velpatasvir (SOF/VEL), and …

Hepatitis C is a global public health threat. The introduction of direct-acting antivirals (DAAs)
brings the prospect of curing the 71 million people living with the disease, dramatically …

Chronic hepatitis C virus (HCV) infection presents a significant global public health burden.
In 2015, over 400000 deaths worldwide were attributed to HCV infection. This led the World …

Infection with hepatitis C virus (HCV) is a major health problem worldwide. A large
proportion of perinatal HCV infections are silent and may present later in adulthood with …

Background/purpose of the study Worldwide and national efforts are directed against
eradication of HCV. The introduction of direct-acting antivirals (DAAs) has changed …

Abstract Background & Aims Treatment of children aged 3‐6 genotype 4 is still limited by the
interferon side effects. We aimed in this study to evaluate the effectiveness and safety of …

Objective To evaluate the safety and efficacy of shortened 8-week regimen of
ledipasvir/sofosbuvir (LED/SOF) combination therapy in treatment-naïve children without …